TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27245312
Drug: AG-120 (mutant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-120 (mutant IDH1 inhibitor)
Study: 27246166
Drug: Patients' self-reported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients' self-reported symptoms collected at baseline and monthly thereafter.
Study: 27247136
Drug: Idelalisib monotherapy
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib monotherapy for 2 months followed by 6 months of combination therapy with idelalisib and ofatumumab
Study: 27247136
Drug: Idelalisib reinitiated
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib reinitiated with steroids
Study: 27247202
Drug: Oral tablets
Normalized name: digoxin 0.1875 MG Oral Tablets
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets
Study: 27247202
Drug: Injectable, implant,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable, implant, or vaginal ring
Study: 27247202
Drug: Vaginal film
Normalized name: Vaginal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal film or suppository
Study: 27252174
Drug: Toca 511
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toca 511 (vocimagene amiretrorepvec) and Toca FC (extended-release 5-fluorocytosine)
Study: 27255328
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment in East Asian patients with T2D
Study: 27255328
Drug: Noninsulin anti-hyperglycemic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninsulin anti-hyperglycemic agents usage
Study: 27255328
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin usage
Study: 27255678
Drug: Sunitinib 25
Normalized name: sunitinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 25 mg (dose level 1)
Study: 27255678
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg (dose level 2)
Study: 27256085
Drug: RSV-attributable antibiotic
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV-attributable antibiotic prescriptions
Study: 27256874
Drug: Lenalidomide and
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide and Sorafenib (sorafenib 400 mg p.o. b.i.d. and lenalidomide 15 mg p.o. daily, with planned dose escalation)
Study: 27258647
Drug: PCV13 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 (two doses, eight weeks apart)
Study: 27258647
Drug: PPSV23 (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPSV23 (one dose)
Study: 27260636
Drug: 40% L-menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% L-menthol applied simultaneously with 10% CA
Study: 27261467
Drug: Panobinostat 20
Normalized name: panobinostat 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat 20 mg orally once daily three times per week
Study: 27262736
Drug: Early uNGAL
Normalized name: miconazole nitrate Topical Cream [Anti-Fungal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early uNGAL excretion
Study: 27262736
Drug: Oliguria (urine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oliguria (urine output <0.5 ml kg(-1) h(-1))
Study: 27265450
Drug: Revaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Study: 27265450
Drug: Primary vaccination
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Study: 27266507
Drug: Augmentation index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation index
Study: 27266697
Drug: Albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole treatment (400 mg administered once every 3 months for 12 months)
Study: 27266697
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (administered once every 3 months for 12 months)
Study: 27266721
Drug: Tac-OD dosing
Normalized name: triamcinolone Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tac-OD dosing based on CYP3A5 genotypes: 0.20 mg/kg/day for CYP3A5*3/*3, 0.25 mg/kg/day for CYP3A5*3/*3, 0.30 mg/kg/day for CYP3A5*1/*3, 0.35 mg/kg/day for CYP3A5*1/*1.
Study: 27266721
Drug: Tac-OD dosing
Normalized name: triamcinolone Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tac-OD dosing based on CYP3A5 genotypes.
Study: 27267107
Drug: central and
Normalized name: INVESTIGATIONAL DRUGS FOR CENTRAL AND PERIPHERAL NEUROPATHY
Approvals — FDA: no, EMA: no, PMDA: no
Description: central and peripheral augmentation index
Study: 27267182
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (Group A) with physical, occupational, speech-language or other conventional rehabilitation therapies.
Study: 27267182
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment group (Group B) with traditional Korean medicine interventions (herbal medicine, chuna, moxibustion, and acupuncture) in addition to conventional treatment.
Study: 27267254
Drug: Ibrutinib (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (140 mg, single oral dose)
Study: 27267608
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg every 2 weeks until progression
Study: 27269295
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg every 4 weeks for 4 months (2 mg/kg for those ≤40 kg)
Study: 27269295
Drug: Canakinumab reintroduced
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab reintroduced on relapse, administered every 4 weeks (increased to every 8 weeks) for 24 months
Study: 27269940
Drug: ipilimumab monotherapy
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab monotherapy
Study: 27269945
Drug: Age, weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, weight group, risk stratification, and nonabsorbable antibiotics
Study: 27269947
Drug: Nivolumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (1 or 3 mg/kg every 2 weeks)
Study: 27270475
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (75-g) and three isocaloric and isovolemic liquid meals with low, medium, and high fat content.
Study: 27271181
Drug: Metformin Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin Therapy
Study: 27272171
Drug: ABT-494 single
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-494 single dose (1-48 mg)
Study: 27272171
Drug: ABT-494 multiple
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-494 multiple dose (3-24 mg twice daily for 14 days)
Study: 27272171
Drug: ABT-494 multiple
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-494 multiple dose (3-24 mg twice daily for 27 days) in RA subjects
Study: 27273860
Drug: Standard-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose intravenous rtPA (0.9mg/kg)
Study: 27275632
Drug: Modified FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FOLFIRINOX treatment (85 mg/m2 of oxaliplatin, 180 mg/m2 of irinotecan hydrochloride, 400 mg/m2 of leucovorin calcium, and 2400 mg/m2 of 5-fluorouracil for 4 cycles) followed by 5.5 weeks of external-beam radiation (50.4 Gy delivered in 28 daily fractions) with capecitabine (825 mg/m2 orally twice daily) prior to pancreatectomy.
Study: 27278794
Drug: Influenza prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza prevention or early intervention with anti-viral treatment
Study: 27279247
Drug: Jejunal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jejunal glucose administration
Study: 27279247
Drug: Gastric glucose
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric glucose administration
Study: 27280017
Drug: Anticoagulants (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (specific type not mentioned, but includes vitamin K antagonists such as warfarin and newer drugs like Xa and thrombin inhibitors)
Study: 27282289
Drug: Fasting for
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting for 24 hours before chemotherapy
Study: 27282289
Drug: Fasting for
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting for 48 hours before chemotherapy
Study: 27282289
Drug: Fasting for
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting for 72 hours before chemotherapy
Study: 27283860
Drug: Dabrafenib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily)
Study: 27285281
Drug: PankoMab-GEX (1-2200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PankoMab-GEX (1-2200 mg, Q3W, Q2W, QW)
Study: 27285281
Drug: PankoMab-GEX (≥1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: PankoMab-GEX (≥1700 mg Q3W)
Study: 27285281
Drug: PankoMab-GEX (≥700
Approvals — FDA: no, EMA: no, PMDA: no
Description: PankoMab-GEX (≥700 mg over 3 weeks)
Study: 27286790
Drug: BEZ235 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 (400 mg b.i.d.)
Study: 27286790
Drug: BEZ235 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 (200 mg b.i.d.)
Study: 27286790
Drug: BEZ235 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 (300 mg b.i.d.)
Study: 27286790
Drug: BEZ235 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 (all doses)
Study: 27287512
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ONCOS-102 with standard of care chemotherapy (Pemetrexed, Cisplatin, Carboplatin)
Study: 27287512
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care chemotherapy (Pemetrexed, Cisplatin, Carboplatin) alone
Study: 27289552
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of chemoresistant circulating tumour cells (CTCs) after adjuvant chemotherapy
Study: 27289552
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of chemoresistant circulating tumour cells (CTCs) after neoadjuvant chemotherapy
Study: 27291511
Drug: Aggressive ICD
Normalized name: ICDMT
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aggressive ICD programming with lower VF detection zone, no antitachycardia pacing therapies during capacitor charge, and shorter detection times.
Study: 27294305
Drug: Rilpivirine 25
Normalized name: rilpivirine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine 25 mg qd
Study: 27296200
Drug: Preprocedural high-sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprocedural high-sensitivity cardiac troponin T (hs-cTnT) elevation (above 14 ng/L)
Study: 27296200
Drug: Normal preprocedural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal preprocedural hs-cTnT (below 14 ng/L)
Study: 27296397
Drug: LCZ696 (sacubitril/valsartan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (sacubitril/valsartan) 200 mg twice daily for 4 to 6 weeks
Study: 27296397
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg twice daily for 2 weeks
Study: 27296397
Drug: Weighted analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weighted analysis of randomized treatment
Study: 27296781
Drug: Standard seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard seed implant (for one patient due to bilateral disease)
Study: 27298069
Drug: Control for
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control for baseline PROMs, septal deviation, steroid-dependent conditions, and medication use variables
Study: 27298729
Drug: One-year group
Normalized name: segesterone
DrugBank: Segesterone (DB14584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-year group multi-professional lifestyle intervention with monthly meetings at the paediatric outpatient obesity clinic (n=65)
Study: 27299735
Drug: Unicirc disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unicirc disposable instrument under topical anesthetic and wound sealing with cyanoacrylate tissue adhesive
Study: 27300475
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg liraglutide daily (acute administration)
Study: 27300475
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg liraglutide daily (chronic administration)
Study: 27300475
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg liraglutide daily (acute and chronic administration)
Study: 27301652
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Dipyrone
Study: 27307708
Drug: Agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agalsidase alfa 0.2 mg/kg every other week for 55 weeks
Study: 27309039
Drug: Hypercaloric diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypercaloric diet (3 g sucrose/kg body weight per day and 1 g fat/kg body weight per day for 28 days)
Study: 27310205
Drug: Sequential Dose-Dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Dose-Dense FOLFOX7 followed by FOLFIRI
Study: 27312051
Drug: Anthracycline-based adjuvant
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based adjuvant chemotherapy in oestrogen receptor-negative breast cancer with high SPAG5 protein expression
Study: 27313069
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide treatment
Study: 27313070
Drug: Birth weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth weight <2500 g
Study: 27313846
Drug: DFA-02 (gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFA-02 (gentamicin 16.8 mg/mL and vancomycin 18.8 mg/mL)
Study: 27315132
Drug: Lacosamide (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (100mg starting dose, titrated up to 400mg/day)
Study: 27315835
Drug: Integrated spasticity
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated spasticity management including multiple botulinum toxin A (BoNT-A) injection cycles and concomitant therapies
Study: 27315835
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy inputs and patient satisfaction with engagement in goal setting
Study: 27317471
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg midazolam (control phase)
Study: 27317471
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg midazolam after pretreatment with 400 mg ketoconazole once daily for 4 days (CYP3A inhibition phase)
Study: 27317471
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg midazolam after pretreatment with 600 mg rifampicin once daily for 10 days (CYP3A induction phase)
Study: 27321869
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (opioids, midazolam, anticholinergics)
Study: 27322029
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake of 1.4 g protein/kg/d during controlled diet and training, followed by variable test diets providing 0.2-2.8 g·kg-1·d-1 protein after exercise.
Study: 27323698
Drug: Statistical definitions
Normalized name: ESIKA PRO HD COLOR HIGH DEFINITION COLOR SPF 20 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical definitions of individual benefit of medical or behavioral treatment using generalized linear mixed-effects models.
Study: 27323698
Drug: Data from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data from the Sequenced Treatment Alternatives to Relieve Depression clinical trial.
Study: 27323698
Drug: Data from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data from a clinical trial of respiratory treatments.
Study: 27324719
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral PrEP (emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF)) for up to 2.5 years
Study: 27324768
Drug: Linezolid (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (standard dosing)
Study: 27325219
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy for multiple attacks
Study: 27325219
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy for pancreas divisum
Study: 27325219
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy for sphincter of Oddi dysfunction (SOD)
Study: 27325604
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral vitamin D
Study: 27325685
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus Capecitabine (Lapatinib 1,250 mg daily and Capecitabine 1,000 mg/m² twice daily for 14 days)
Study: 27325859
Drug: Hemithoracic intensity-modulated
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) administered at a planned dose of 50.4 Gy in 28 fractions.
Study: 27326862
Drug: Insulin analogue
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogue regimen
Study: 27326862
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin regimen
Study: 27328699
Drug: hsCRP >3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP >3.0 mg/L
Study: 27329247
Drug: PF-03446962 7
Normalized name: Aminosyn-PF 7%
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PF-03446962 7 mg/kg intravenously biweekly
Study: 27330808
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose denileukin diftitox (18 mcg/kg) prior to vaccination
Study: 27330808
Drug: 4-peptide vaccine
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-peptide vaccine (Melan-A, gp100, MAGE3 and NA17 with GM-CSF emulsified in Montanide) alone
Study: 27331367
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of LPS via MB2 nebulizer (3.2 μm)
Study: 27331367
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of LPS via Pari nebulizer (7.9 μm)
Study: 27331367
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of LPS via Microcirrus nebulizer (2.0 μm)
Study: 27331367
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of large droplets of LPS
Study: 27333947
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) administered as a single 600 mg dose followed by multiple doses to steady-state.
Study: 27333947
Drug: Efavirenz concentrations
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz concentrations exceeding 0.4 μg/mL.
Study: 27334671
Drug: Bisoprolol/amlodipine FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol/amlodipine FDC 5/5 mg OD
Study: 27334671
Drug: Bisoprolol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol monotherapy failure
Study: 27334671
Drug: Amlodipine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine monotherapy failure
Study: 27335027
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg every 3 weeks) in combination with chemotherapy
Study: 27335883
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (5 mgs/kg)
Study: 27336356
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone administration
Study: 27338133
Drug: Low-normal TSH
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-normal TSH levels (≤2.5 mU/L)
Study: 27338133
Drug: High-normal TSH
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-normal TSH levels (>2.5 mU/L)
Study: 27338143
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy (etanercept)
Study: 27338191
Drug: Interval training,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval training, details on dosage and duration not available
Study: 27340749
Drug: Olipudase alfa
Normalized name: OLIPUDASE ALFA
DrugBank: Olipudase alfa (DB12835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olipudase alfa (recombinant human ASM) administered every 2 weeks for 26 weeks
Study: 27342239
Drug: Idarubicin 5
Normalized name: IDArubicin 5 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin 5 mg
Study: 27342239
Drug: Idarubicin 10
Normalized name: IDArubicin 10 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin 10 mg
Study: 27342239
Drug: Idarubicin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin 15 mg
Study: 27342743
Drug: Previous use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous use of hormonal treatment for endometriosis
Study: 27342748
Drug: Omegaven (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omegaven (intravenous infusion of omega-3 polyunsaturated fatty acids)